Today: 19 June 2026

Exxon stock jumps after Q4 upstream warning; oil rebound and Jan. 30 earnings loom

Exxon stock jumps after Q4 upstream warning; oil rebound and Jan. 30 earnings loom

Exxon Mobil shares rose 3.7% in after-hours trading after a filing warned of a possible $0.8–$1.2 billion hit to Q4 upstream earnings from weaker crude prices. The company cited stronger refining margins as a potential offset. Investors are watching for Exxon’s Jan. 30 earnings and Friday’s U.S. jobs report. Oil prices surged over 3% Thursday amid global supply concerns.
9 January 2026
···
Ondas (ONDS) stock jumps 15% after-hours as SEC resale filing and insider sale notice hit tape

Ondas (ONDS) stock jumps 15% after-hours as SEC resale filing and insider sale notice hit tape

Ondas Holdings shares jumped 14.9% to $14.01 after hours Thursday after registering 1.67 million shares for resale tied to its Sentry CS acquisition. A Form 144 showed former director Ron Stern planned to sell up to 300,000 shares following an options exercise. The company will not receive proceeds from the registered resale shares. CEO Eric Brock is scheduled to speak at Needham’s Growth Conference on Jan. 14.
9 January 2026
·
Lockheed Martin stock jumps as Trump floats $1.5 trillion defense budget, buyback limits in focus

Lockheed Martin stock jumps as Trump floats $1.5 trillion defense budget, buyback limits in focus

Lockheed Martin shares rose 4.3% to $518.44 in after-hours trading Thursday after a volatile session. The move followed a White House order restricting dividends and buybacks for underperforming defense contractors. Lockheed recently reported record F-35 deliveries and a new missile production deal but faces uncertainty over tighter payout rules and executive pay scrutiny. Fourth-quarter results are due Jan. 29.
9 January 2026
··
Robinhood stock slips after CEO share sale; jobs report and Feb. 10 earnings set the next test

Robinhood stock slips after CEO share sale; jobs report and Feb. 10 earnings set the next test

Robinhood shares fell 1.4% to $115.39 in after-hours trading after filings showed CEO Vlad Tenev sold 375,000 shares worth $45.6 million under a pre-set plan. The stock moved between $113.90 and $117.30 during the regular session. Investors await Friday’s U.S. jobs report for rate clues and Robinhood’s Feb. 10 earnings release. Crypto markets and peer broker stocks also edged lower.
9 January 2026
··
Ford stock jumps nearly 5% on Piper Sandler upgrade as investors look past EV cuts

Ford stock jumps nearly 5% on Piper Sandler upgrade as investors look past EV cuts

Ford shares rose 4.8% to $14.40 in after-hours trading Thursday after Piper Sandler upgraded the stock and raised its price target to $16. General Motors recorded a $6 billion charge tied to reduced EV investments as Detroit automakers shift focus amid weaker demand and the end of federal tax credits. Ford’s U.S. sales climbed 6% in 2025, with hybrid sales up nearly 22%.
9 January 2026
··
Opendoor stock pops after Trump targets big homebuyers as CEO insists firm “doesn’t hold the homes”

Opendoor stock pops after Trump targets big homebuyers as CEO insists firm “doesn’t hold the homes”

Opendoor shares climbed up to 5% Thursday after CEO Kaz Nejatian said the company is not a large institutional homebuyer, distancing it from President Trump’s proposed ban on institutional single-family home purchases. Housing stocks including Invitation Homes and American Homes 4 Rent fell sharply after Trump’s announcement. Analyst targets for Opendoor remain below its current price.
9 January 2026
·····
Walmart stock inches up after-hours on board pick as Barclays, Oppenheimer lift targets

Walmart stock inches up after-hours on board pick as Barclays, Oppenheimer lift targets

Walmart shares rose 0.3% to $113.07 in after-hours trading Thursday after the company named Superhuman CEO Shishir Mehrotra to its board. Barclays and Oppenheimer raised their Walmart price targets to $125 this week. Mehrotra will serve on the compensation and technology committees. Investors await Walmart’s ICR conference update on Jan. 13 and its Feb. 19 earnings report.
9 January 2026
·
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly shares fell 2.1% after hours to $1,085.19 following late-stage data showing its Zepbound-Taltz combo met dual goals in 31.7% of psoriatic arthritis patients, versus 0.8% for Taltz alone. The company also agreed to buy Ventyx Biosciences for $1.2 billion and disclosed a $322.4 million share sale by Lilly Endowment Inc. Investors await updates at the J.P. Morgan Healthcare Conference next week.
9 January 2026
··
Applied Digital (APLD) stock jumps after earnings beat as AI data-center lease talks stay in focus

Applied Digital (APLD) stock jumps after earnings beat as AI data-center lease talks stay in focus

Applied Digital shares climbed 8% to $31.94 in after-hours trading Thursday after quarterly revenue beat estimates, reaching $126.6 million. The company highlighted new long-term leases for AI data centers and said its Polaris Forge 1 site delivered 100 megawatts on schedule. Cash and equivalents totaled $1.91 billion as of Nov. 30, with $2.59 billion in long-term debt. Investors await further lease conversions and Friday’s U.S. jobs report.
9 January 2026
····
ISS medical issue forces NASA to send Crew-11 home early, scrapping spacewalk

ISS medical issue forces NASA to send Crew-11 home early, scrapping spacewalk

NASA ordered SpaceX Crew-11 to return early from the International Space Station after a medical issue involving one astronaut, who is stable. A planned Jan. 8 spacewalk was canceled. NASA has not released the crew member’s name or details of the condition. The agency will announce a new undock and re-entry schedule within two days.
9 January 2026
Microsoft stock slips after Copilot Checkout push; MSFT earnings loom

Microsoft stock slips after Copilot Checkout push; MSFT earnings loom

Microsoft shares fell 1.1% to $478.11 in after-hours trading Thursday, tracking declines in other tech stocks as the Nasdaq slipped 0.44%. The company announced the U.S. launch of Copilot Checkout, a chat-based shopping tool partnering with PayPal, Shopify, and Stripe. Investors remain cautious about AI spending translating into revenue. Microsoft reports fiscal Q2 results on Jan. 28.
9 January 2026
·····
AMD stock falls 2.5% as tech retreats, Feb. 3 earnings and CES AI chips in focus

AMD stock falls 2.5% as tech retreats, Feb. 3 earnings and CES AI chips in focus

AMD shares fell 2.5% to $204.68 after market close Thursday, mirroring declines in chip stocks and broader tech. Investors are watching for AMD’s Feb. 3 earnings report, focused on data-center accelerator shipments after new chip unveilings at CES. CEO Lisa Su highlighted the MI455 and MI440X processors, targeting Nvidia’s market share. CTO Mark Papermaster will speak at a Morgan Stanley conference on March 3.
9 January 2026
···
Sandisk stock slips in late trade after AI-storage rally cools — what investors watch next

Sandisk stock slips in late trade after AI-storage rally cools — what investors watch next

Sandisk shares fell 5.3% to $334.54 in after-hours trading Thursday, extending a sharp drop after a volatile session that erased part of this week’s CES-driven surge. The stock, up over 800% since its 2025 spinoff, has swung on AI infrastructure bets and will report fiscal Q2 results on Jan. 29.
9 January 2026
······
1 … 947 948 949 950 951 … 2,085

Stock Market Today

  • uniQure Shares Surge 78% on FDA Support for AMT-130 Accelerated Approval
    June 19, 2026, 3:49 PM EDT. uniQure's stock jumped 78.4% after the FDA indicated that three-year phase I/II data for AMT-130, a gene therapy for Huntington's disease, could support a biologics license application (BLA) for accelerated approval. The FDA requested alignment on a confirmatory study design, favoring a control group over sham surgery, with plans expected before a 2026 Q3 BLA filing. This update follows earlier regulatory setbacks when the FDA questioned the sufficiency of phase I/II data compared to external controls. AMT-130 uses gene-silencing microRNA to target the huntingtin gene. The therapy is evaluated in ongoing phase I/II trials assessing safety and efficacy. uniQure aims to begin confirmatory studies promptly under FDA collaboration.

Latest articles

WELL Health slides as TSX holds steady; Circle Medical, cash flow draw attention

WELL Health slides as TSX holds steady; Circle Medical, cash flow draw attention

19 June 2026
WELL Health plunged 3.7% to C$4.19 in Toronto as investors looked past director election results and focused on falling Q1 operating adjusted free cash flow, which dropped to C$1.6 million from C$11.8 million a year earlier due to clinic investments, higher cash taxes, Circle Medical deferrals, and increased interest payments.
MDA Space stock rises as Blue Canyon deal targets U.S. defense market

MDA Space stock rises as Blue Canyon deal targets U.S. defense market

19 June 2026
MDA Space’s Toronto shares jumped 4.4% to C$58.08 after it agreed to buy Blue Canyon Technologies from RTX’s Raytheon for US$620 million cash, a move aimed at expanding access to U.S. defense-space work and classified programs; the deal is expected to add to adjusted EBITDA and EPS in 2027 but faces regulatory approval and integration risks.
Fermi rally stalls with Nasdaq closed for Juneteenth as proxy fight simmers

Fermi rally stalls with Nasdaq closed for Juneteenth as proxy fight simmers

19 June 2026
Fermi surged 10% to $9.50 before the Juneteenth market closure, fueled by speculation of a potential OpenAI-related customer for its Project Matador campus, but no binding tenant deal has been announced, leaving the rally exposed to profit-taking if a concrete agreement or joint venture isn’t revealed when trading resumes.
Go toTop